6 active not recruiting, 3 completed, 1 recruiting, 1 unknown. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 6, Completed 3, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow Recurrent Malignant Glioma: new trials by email Literature Review of Recurrent Malignant Glioma trials Research Report on Recurrent Malignant Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma OKN-007, Temozolomide (TMZ) - Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | Completed | Oblato, Inc. | 57 | 2020-06-12 | 2025-08-12 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Bevacizumab / Irinotecan - Recurrent Malignant Glioma | Phase 2 | Unknown | Medical University Innsbruck | 35 | 2010-03-01 | 2011-08-02 |
| Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma IL13-PE38QQR - Recurrent Malignant Glioma | Phase 1 / Phase 2 | Withdrawn | INSYS Therapeutics Inc | 2014-11-13 |
Glioma (12) · Ependymoma (9) · Medulloblastoma (9) · Hepatoblastoma (8) · Histiocytosis, Langerhans-Cell (8) · Lymphoma, Non-Hodgkin (8) · Neuroblastoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (8) · Rhabdoid Tumor (8) · Wilms Tumor (8) · Osteosarcoma (7) · Rhabdomyosarcoma (7) · Sarcoma (7) · Central Nervous System Neoplasms (5) · Sarcoma, Ewing (5)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Glandular and Epithelial (12) · Neoplasms, Nerve Tissue (12) · Neoplasms, Neuroepithelial (12) · Neuroectodermal Tumors (12) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms by Site (9) · Neuroectodermal Tumors, Primitive (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8) · Hemic and Lymphatic Diseases (8) · Histiocytosis (8)
Magnetic Resonance Spectroscopy (4) · Nuclear Medicine Department, Hospital (4) · Phantoms, Imaging (4) · X-Rays (4) · Biopsy (3) · Specimen Handling (3) · Bevacizumab (1) · IL13-PE38 (1) · Irinotecan (1) · OKN 007 (1) · Temozolomide (1) · disufenton sodium (1) · ensartinib (1) · erdafitinib (1) · ivosidenib (1)
National Cancer Institute (NCI) (8) · INSYS Therapeutics Inc (1) · Medical University Innsbruck (1) · Nationwide Children's Hospital (1) · Oblato, Inc. (1)
United States (11) · Puerto Rico (8) · Australia (3) · Austria (1) · Canada (1)
Alice Lee (1) · Andrea T Franson (1) · Anuradha Banerjee, MD, MPH (1) · Christine A Pratilas (1) · Elizabeth D Alva (1) · Guenther Stockhammer, MD, Prof. (1) · Katherine A Janeway (1) · Margot Lazow, MD (1) · Meredith S Irwin (1) · Rajen Mody (1) · Susan N Chi (1)
PMID 31401903, PMID 34486544, PMID 39298716, PMID 42853672, PMID 42867148
U10CA180886 (8), UM1CA081457 (1)